title: Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?
authors.affiliation: Diabetology, Careggi Teaching Hospital, Florence, Italy.
authors.forename: Ilaria
authors.initials: I
authors.lastname: Dicembrini
authors.affiliation: Diabetology, Careggi Teaching Hospital, Florence, Italy. Electronic address: edoardo.mannucci@unifi.it.
authors.forename: Edoardo
authors.initials: E
authors.lastname: Mannucci
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004151:Dipeptides / Q000494:pharmacology*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology; D006801:Humans; D015994:Incidence; D009203:Myocardial Infarction / Q000453:epidemiology / Q000209:etiology; D063868:Patient Outcome Assessment; D018579:Patient Selection; D010880:Piperidines / Q000494:pharmacology*; D012107:Research Design; D013997:Time Factors; D014498:Uracil / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D010880:Piperidines; D014498:Uracil; C502994:saxagliptin; C520853:alogliptin; D000218:Adamantane
keywords: Dipeptidyl Peptidase 4 inhibitors; Myocardial infarction; Type 2 diabetes